Target Pipelines

Showing 41–50 of 50 results

  • May of 2022
    This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities
     500.00
  • April of 2020
    This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.
     150.00
  • February of 2020
    This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.
     100.00
  • September of 2019
    This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.
     250.00
  • July of 2019
    This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.
     150.00
  • June of 2019
    This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.
     50.00
  • May of 2019
    This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)
     150.00
  • April of 2019
    This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.
     50.00
  • December of 2018
    This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
     75.00
  • January of 2019
    This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.
     100.00